Examining patient outcomes following different regimens of biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) in the large, multinational, IMPROVE™ observational study

被引：0

作者：

Ligthelm, R. J. ^{[1
]}

Valensi, P. ^{[2
]}

van der Lubbe, W. ^{[3
]}

机构：

[1] EHM Clin Hoofddorp, Rotterdam, Netherlands

[2] Univ Paris Nord, Jean Verdier Hosp, Dept Endocrinol, Bondy, France

[3] Novo Nordisk AS, Global Mkt, DK-2880 Bagsvaerd, Denmark

来源：

DIABETOLOGIA | 2009年 / 52卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

214

引用

页码：S94 / S94

页数：1

共 50 条

[1] Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
Gumprecht, J.
Benroubi, M.
Borzi, V.
Kawamori, R.
Shaban, J.
Shah, S.
Shestakova, M.
Wenying, Y.
Ligthelm, R.
Valensi, P.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (06) : 966 - 972
[2] The pharmacokinetic and pharmacodynamic properties of biphasic insulin aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin aspart 30 (BIAsp 30)
Bott, S
Tusek, C
Heinemann, L
Friberg, HH
Heise, T
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (09) : 545 - 550
[3] Biphasic Insulin Aspart 30/70 (BIAsp 30) Is Well Tolerated Effective in Patients ≥75 Years Old in the IMPROVE™ Study
Borzi, Vito
Rosenberg, Kristine Horn
Benroubi, Marian
DIABETES, 2010, 59 : A554 - A555
[4] Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
Valensi, Paul
DIABETES METABOLIC SYNDROME AND OBESITY, 2009, 2 : 61 - 71
[5] Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study
Valensi, P.
Benroubi, M.
Borzi, V.
Gumprecht, J.
Kawamori, R.
Shaban, J.
Shah, S.
Shestakova, M.
Wenying, Y.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (03) : 522 - 531
[6] Biphasic Insulin Aspart 30 (BIAsp 30) Improves Glycemic Control in Patients with Type 2 Diabetes Regardless of Previous Treatment Regimens: The IMPROVE Study in Iran
Esteghamati, Alireza
Rajabian, Reza
Amini, Masoud
Bahrami, Amir
Khamseh, Mohammad Ebrahim
Ardekani, Mohammad
Rizi, Ehsan Parvaresh
DIABETES, 2009, 58 : A516 - A516
[7] Patient treatment satisfaction improves after switching to NovoMix® 30 (BIAsp 30):: The IMPROVE™ study data
Yang Wenying
Christensen, Torsten
Kawamori, Ryuzo
DIABETES, 2008, 57 : A584 - A584
[8] Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: results from a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 in routine clinical practice
Shestakova, M. V.
Akil, Ballan
DIABETES MELLITUS, 2010, 13 (01): : 92 - 100
[9] IMPROVE (TM) observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus
Kawamori, Ryuzo
Valensi, Paul
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (04) : 507 - 516
[10] Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: A multicenter, observational, primary care study conducted in Finland
Makela, Jyrki K.
Schmuser, Christine
Askonen, Kari
Saukkonen, Tero
DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 95 (01) : 10 - 18

← 1 2 3 4 5 →